You searched for cellectis - Page 10 of 12

News and Trends 8 Feb 2016

The European Union Finances the Future of CAR-T Manufacturing

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a more unified approach to CAR-T under a European Union Commission program. In response to this major health issue Miltenyi Biotec (Germany) coordinates the new EU-funded project […]

February 8, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Feb 2016

Huge Milestone: UK Approves CRISPR Editing on Human Embryos

This could be a HUGE game-changer for Europe’s research on stem cells, and more broadly Gene Editing…. Research on human embryos is a very touchy subject. And when you want to allow the use of the most powerful gene-editing tool on them, it’s becomes even touchier. Research on human embryos has been forbidden almost everywhere (with exception to China […]

February 1, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

cancer biotech killers deadliest oncology therapies immunooncology

News and Trends 19 Jan 2016

Top 8 Deadliest Cancers and their Potential Cures

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost…and there lies hope in the Biotech Industry. Simply by having a quick look through our articles, we can easily confirm that cancer is […]

January 19, 2016 - 7 minutesmins - By Dani Bancroft

News and Trends 12 Jan 2016

10 Hot European Biotechs to watch in 2016

Looking forward to 2016, I wondered which Biotechs I would watch closely. Here’s my list (which is not meant to be extensive and is in no particular order): 1. Immunocore – Oxford, UK Immunocore is developing TCR-based immuno-oncology treatments and has raised nearly €300M ($320M) in its last round of private fundraising – a pure anomaly […]

January 12, 2016 - 6 minutesmins - By Philip Hemme

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

News and Trends 30 Dec 2015

3 EU Biotechs which Over-performed in 2015

2015 was a crazy year for the Biotech industry, probably the craziest since the birth of the industry 40 years ago. I looked back on this year and here’s my personal top 3 of EU Biotechs which over-performed. I sorted them out in top partnerships, clinical trials and fundraising. (Of course, this lists is not […]

December 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Dec 2015

The Review of Reviews – the Best Ones of 2015!

As you all are aware of this year, we have published a lot of brilliant reviews on some of the hottest topics in the Biotech Industry! This article highlights our favourite ones for 2015! Click the titles to read more… Review: The CRISPR’s Therapeutical revolution CRISPR has an enormous potential in therapeutic development and many […]

December 28, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us